183 related articles for article (PubMed ID: 12397170)
1. Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia.
Dressler D
J Neurol Neurosurg Psychiatry; 2002 Nov; 73(5):604; author reply 604. PubMed ID: 12397170
[No Abstract] [Full Text] [Related]
2. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
3. New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia.
Dressler D; Adib Saberi F
J Neurol Neurosurg Psychiatry; 2007 Jan; 78(1):108-9. PubMed ID: 17172580
[No Abstract] [Full Text] [Related]
4. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
Ranoux D; Gury C; Fondarai J; Mas JL; Zuber M
J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):459-62. PubMed ID: 11909903
[TBL] [Abstract][Full Text] [Related]
5. Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?
Duarte GS; Rodrigues FB; Ferreira JJ; Costa J
Parkinsonism Relat Disord; 2018 Nov; 56():16-19. PubMed ID: 29910156
[TBL] [Abstract][Full Text] [Related]
6. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
7. Systemic effect of local and small-dose botulinum toxin injection to unmask subclinical myasthenia gravis.
Iwase T; Iwase C
Graefes Arch Clin Exp Ophthalmol; 2006 Mar; 244(3):415-6. PubMed ID: 16175373
[No Abstract] [Full Text] [Related]
8. Botulinum toxin (Botox, Dysport, and Myobloc): pharmacology 101.
Wynn RL
Gen Dent; 2011; 59(2):88-90. PubMed ID: 21903516
[No Abstract] [Full Text] [Related]
9. Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia.
Rystedt A; Nyholm D; Naver H
Clin Neuropharmacol; 2012; 35(6):278-82. PubMed ID: 23123690
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of focal dystonia with botulinum toxin A].
Sojer M; Wissel J; Müller J; Poewe W
Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.
Kazerooni R; Broadhead C
Am J Health Syst Pharm; 2015 Feb; 72(4):301-7. PubMed ID: 25631837
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A therapy for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD003633. PubMed ID: 15674910
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.
Rystedt A; Zetterberg L; Burman J; Nyholm D; Johansson A
Clin Neuropharmacol; 2015; 38(5):170-6. PubMed ID: 26366966
[TBL] [Abstract][Full Text] [Related]
14. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.
Vergilis-Kalner IJ
J Drugs Dermatol; 2011 Sep; 10(9):1013-5. PubMed ID: 22052270
[TBL] [Abstract][Full Text] [Related]
15. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
Yun JY; Kim JW; Kim HT; Chung SJ; Kim JM; Cho JW; Lee JY; Lee HN; You S; Oh E; Jeong H; Kim YE; Kim HJ; Lee WY; Jeon BS
Mov Disord; 2015 Feb; 30(2):206-13. PubMed ID: 25476727
[TBL] [Abstract][Full Text] [Related]
16. Xeomin(®) use in patients with systemic immune reactions to other botulinum toxins type A.
Ricciardi L; Bove F; Fasano A
Eur J Neurol; 2013 Mar; 20(3):e45-e46. PubMed ID: 23406455
[No Abstract] [Full Text] [Related]
17. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia.
Odergren T; Hjaltason H; Kaakkola S; Solders G; Hanko J; Fehling C; Marttila RJ; Lundh H; Gedin S; Westergren I; Richardson A; Dott C; Cohen H
J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):6-12. PubMed ID: 9436720
[TBL] [Abstract][Full Text] [Related]
18. Relapsing-remitting severe generalized muscular weakness after botulinum toxin treatment for hyperhidrosis.
Chiarello D; Piombo M; Corbetto M; Di Pino G; Assenza G; Capone F; Di Lazzaro V
Muscle Nerve; 2014 Sep; 50(3):456-7. PubMed ID: 24890202
[No Abstract] [Full Text] [Related]
19. Cervical dystonia: clinical and therapeutic features in 85 patients.
Camargo CH; Teive HA; Becker N; Baran MH; Scola RH; Werneck LC
Arq Neuropsiquiatr; 2008 Mar; 66(1):15-21. PubMed ID: 18392407
[TBL] [Abstract][Full Text] [Related]
20. Is Botulinum Toxin Type A Efficacious, Safe, and Tolerable in Cervical Dystonia?: A Cochrane Review Summary With Commentary.
Oral A
Am J Phys Med Rehabil; 2020 Jul; 99(7):649-651. PubMed ID: 32251106
[No Abstract] [Full Text] [Related]
[Next] [New Search]
